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Abstract
Objectives Compare the performance of zone-specific multi-parametric-MRI (mp-MRI) diagnostic models in prostate cancer
detection with experienced radiologists.
Methods A single-centre, IRB approved, prospective STARD compliant 3 T MRI test dataset of 203 patients was generated to
test validity and generalisability of previously reported 1.5 T mp-MRI diagnostic models. All patients included within the test
dataset underwent 3 T mp-MRI, comprising T2, diffusion-weighted and dynamic contrast-enhanced imaging followed by
transperineal template ± targeted index lesion biopsy. Separate diagnostic models (transition zone (TZ) and peripheral zone
(PZ)) were applied to respective zones. Sensitivity/specificity and the area under the receiver operating characteristic curve
(ROC-AUC) were calculated for the two zone-specific models. Two radiologists (A and B) independently Likert scored test
3 T mp-MRI dataset, allowing ROC analysis for each radiologist for each prostate zone.
Results Diagnostic models applied to the test dataset demonstrated a ROC-AUC = 0.74 (95% CI 0.67–0.81) in the PZ and 0.68
(95% CI 0.61–0.75) in the TZ. Radiologist A/B had a ROC-AUC = 0.78/0.74 in the PZ and 0.69/0.69 in the TZ. Radiologists A
and B each scored 51 patients in the PZ and 41 and 45 patients respectively in the TZ as Likert 3. The PZ model demonstrated a
ROC-AUC = 0.65/0.67 for the patients Likert scored as indeterminate by radiologist A/B respectively, whereas the TZ model
demonstrated a ROC-AUC= 0.74/0.69.
Conclusion Zone-specific mp-MRI diagnostic models demonstrate generalisability between 1.5 and 3 T mp-MRI protocols and
show similar classification performance to experienced radiologists for prostate cancer detection. Results also indicate the ability
of diagnostic models to classify cases with an indeterminate radiologist score.
Key Points
• MRI diagnostic models had similar performance to experienced radiologists for classification of prostate cancer.
• MRI diagnostic models may help radiologists classify tumour in patients with indeterminate Likert 3 scores.
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Introduction
Multi-parametric MRI (mp-MRI) has heralded a paradigm shift
in the management of prostate cancer. It is now commonly
employed to localise suspicious areas within the prostate and
facilitate targeted histological sampling [1]. Nevertheless, mp-
MRI remains an imperfect test. For example, between 30 and
40% of mp-MRI studies, even by experienced radiologists, are
scored as indeterminate for cancer (Likert/PIRADS 3) [2, 3]. An
indeterminate mp-MRI confers little benefit. Most patients with
indeterminatemp-MRI-scored studies do not have cancer within
the gland [3]. However, a significant minority harbour small
volume Gleason 3 + 4 disease or more widespread Gleason
3 + 3 disease [4]. An indeterminate study results in a manage-
ment dilemma of whether to perform a biopsy. Not performing
the biopsy risks underdiagnosing patients with significant pros-
tate cancer, whilst performing a biopsy risks over the investiga-
tion of patients with likely insignificant or no cancer.
Furthermore, mp-MRI also misses approximately 10% of cases
of significant prostate tumour [4]. There remains a need to im-
prove the performance of mp-MRI.
One potential approach to address these challenges has
been to develop diagnostic models based on quantitative
mp-MRI metrics. For example, we have previously derived
zone-specific logistic regression (LR) models for classifica-
tion of significant prostate cancer [5, 6]. Others have also
developed similar models [7–9]. However, whilst studies
based on internal validations suggest an overall good perfor-
mance, it is recognised that this performance may be an over-
estimate and not generalisable to other (external) datasets.
Within this study, we aimed to assess the external validity
of our previously derived and internally validated mp-MRI
LR models [5, 6]. Specifically, we apply the zone-specific
LR models, derived on a Siemens 1.5 T mp-MRI dataset, for
the classification of an independent cohort of patients imaged
using a Philips 3 T scanner.
In order to evaluate the potential clinical value of LR
models, we compare their overall performance against expe-
rienced radiologists for classification of patients with
significant prostate cancer and determine whether LR models
could be applied for the classification of indeterminate (Likert
3/5) scored cases.
Material and methods
Our local institutional review board approved the study and
waived the requirement for individual consent for retrospec-
tive analysis of patient data collected as part of clinical trials/
routine care (R&D No: 12/0195; date: 16 July 2012).
Patient population
A single centre, IRB approved, prospective STARD compli-
ant trial dataset of 330 patients [4] was reviewed. Three hun-
dred thirty men (median age of 63 years, interquartile range,
IQR [42–83]; median prostate-specific antigen (PSA) of
7.4 ng/ml, IQR [0.7–58.05]), with previous negative/ non-
significant prostate disease on transrectal ultrasound (TRUS)
biopsies, but in whom a clinical suspicion of prostate cancer
remained, were consecutively enrolled from 11 January 2012
to 29 January 2014. All patients underwent 3 T mp-MRI
(Achieva, Philips Healthcare) of the prostate. All studies were
prospectively scored using a Likert scale by an experienced
radiologist (radiologist A; with 14 years of experience in pros-
tate mp-MRI and reporting more than 500 mp-MRI scans/
year). Patients then underwent transperineal templatemapping
biopsies of the whole gland (irrespective or radiologist report)
± MR-targeted biopsy of a suspected index lesion (based on
the radiologist report) as described within the PICTURE study
protocol [4]. In summary, mapping using 5 mm sampling was
obtained using core needles inserted via a brachytherapy grid
fixed on a stepper. In most prostates, two biopsies at each grid
point were required to sample the full craniocaudal gland
length. Two to three targeted biopsies were performed for
the mp-MRI index lesion-scored Likert 3 or above. In total,
90% of the patients underwent the additional targeted biopsy.
To derive a complete dataset of patients scanned at 3 T, men
were selected with the following criteria: (i) a full template
biopsy ± targeted biopsy and (ii) a complete 3 T mp-MRI
comprising of T2W, diffusion-weighted (DW) and dynamic
contrast-enhanced (DCE) imaging. One hundred twenty-
seven patients did not meet the inclusion criteria; 5 had mp-
MRI performed at 1.5 T, 11 had incomplete mp-MRI datasets,
71 did not undergo the full template biopsy due to clinical
circumstances, 13 patients were excluded due to post-biopsy
artefacts, 12 patients were excluded due to distorted DWI and
15 patients were excluded where cancer was present in both
the PZ and the TZ (Fig. 1). Two hundred three patients with
median age 65.4 years (interquartile range, IQR = 42.9–86)
and median PSA of 7.2 ng/ml (IQR = 2.1–32.4) formed the
final test dataset.
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Of the 203men included in the final dataset, 89 had biopsy-
confirmed significant cancer (see the BHistological reference
standard^ section) within the TZ and 110 biopsies confirmed
significant cancer within the PZ. Median PSA of patients with
significant cancer within the PZ and TZ was 7.22 ng/ml and
6.52 ng/ml respectively. Median PSA of patients with benign
histology or non-significant cancer only within the PZ and TZ
was 7.02 ng/ml and 7.77 ng/ml respectively.
A second radiologist (radiologist B, with 5 years of expe-
rience in prostate mp-MRI and reporting more than 1200 mp-
MRI scans/year) retrospectively re-reported each of the 203
patient’s study, unaware of radiologist A’s original report and
histological results.
As Likert scoring has been prospectively validated within
multicentre PROMIS trial [10] and is the scoring method rec-
ommended byUK consensus [11], both radiologists (A and B)
used the Likert scale to score the presence of significant dis-
ease within each prostate zone.
Multi-parametric MRI protocol
The full details of the mp-MRI performed as part of the
PICTURE trial have been previously reported [4]. In brief,
MRI was performed on a single 3 T scanner (Achieva,
Philips Healthcare) using a 32-channel cardiac phased-array
coil. Prior to imaging, 0.2 mg/kg (up to 20 mg) of a spasmo-
lytic agent (Buscopan; Boehringer Ingelheim) was adminis-
tered intravenously to reduce bowel peristalsis. Axial and cor-
onal T2-weighted images were acquired with TR/TE = 5407/
100ms, flip angle = 90°, field of view = 180mm, a 3-mm slice
thickness and slice centre-to-centre separation of 3 mm. Axial
DW images were acquired at b = 0, 150, 500, 1000, and
2000 s/mm2 with TR/TE = 2753/80 ms, flip angle = 90°, field
of view = 220 mm and a 5-mm slice thickness. A high b value
at b = 2000 s/mm2 was included to evaluate the interstitial free
water and permeability. An axial apparent diffusion coeffi-
cient (ADC) map was generated automatically from DW im-
ages at b = 0, 150, 500, and 1000 s/mm2. DCE was performed
with a T1-weighted volumetric sequence (TR/TE = 5.8/28ms,
flip angle = 10°, field of view = 180 mm, slice thickness =
3 mm, temporal resolution of 15 s) before and after intrave-
nous administration of at least 0.1 mmol/kg gadolinium
meglumine contrast agent (Dotarem®, Guerbet) at a rate of
3 ml/s via power injector, followed by 20ml saline bolus at the
same rate.
Radiologist Likert scoring
Radiologists used a 12-segment (anterior/posterior, left/right,
and division into the apical/middle/basal thirds) prostate pic-
torial reporting proforma to provide Likert scores for each
segment together with drawing and scoring any identified fo-
cal lesions. For each patient, the highest Likert score given by
each radiologist for each zone is summarised in Table 1.
Figures 2 and 3 (in the PZ and the TZ respectively) show
examples of the regions with positive template mapping biop-
sy (TPM) biopsy that were independently scored as indeter-
minate (Likert = 3) by both experienced radiologists.
Histological reference standard
The PICTURE study employed TPM biopsy ± targeted biop-
sy of the suspected index lesion as previously described [4]. A
TPM histological reference standard (as compared with pros-
tatectomy reference) provides the opportunity to collect true-
negative as well as true-positive cases. It has a reported sen-
sitivity of 95% and negative predictive value of 95% for clin-
ically significant cancers of volume > 0.5 cm3 and 76% sen-
sitivity for all cancers [12–14].
An experienced (12 years) prostate pathologist analysed all
biopsy cores blinded to the mp-MRI findings. Significant can-
cer was defined, based on previously reported TPM biopsy
Fig. 1 Flowchart outlining the study
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criteria [15], as the presence of anyGleason 4 tumour (primary
or secondary pattern) or Gleason 3 + 3 tumour with a maxi-
mum cancer core length threshold 4 mm.
Quantitative evaluation of mp-MRI
The test mp-MRI datasets were analysed with MIM
Symphony Version 6.1 (MIM Software Inc.). Following radi-
ologist scoring, the two radiologists were unblinded to each
other’s mp-MRI reports and the histological reference stan-
dard. The radiologists, in consensus, manually contoured the
regions of interest (ROI) on mp-MRI (T2-weighted images,
apparent diffusion coefficient (ADC) maps and contrast early-
enhanced T1-weighted images) to allow the extraction of
quantitative mp-MRI metrics from regions of significant can-
cer and also from areas confirmed to have benign histology.
Specifically, where visible, the index lesion contain-
ing significant cancer within each zone (PZ and TZ)
was contoured on each imaging sequence. Where no
lesion was evident (even in retrospect) on mp-MRI
and histological confirmed significant cancer was pres-
ent, the radiologists contoured a 1-cm2 ROI at the his-
tologically confirmed location of cancer. Where no le-
sion was visualised and/or no significant cancer present
within a zone/lesion, the radiologists avoided the areas
with histologically confirmed insignificant disease and
contoured a 1-cm2 ROI at a histologically confirmed
benign location.
The mean signal intensity (SI) of each ROI on the corre-
sponding T2-weighted images, ADC maps and early T1 arte-
rial contrast-enhanced images was recorded. T2 and early T1
arterial contrast-enhanced SI were normalised against a right
obturator internus ROI to give normalised T2 (T2-nSI) and
normalised early dynamic contrast-enhanced SI (DCE-nSI)
parameters. The maximum enhancement (ME) parameter
was also derived from the DCE signal enhancement time
curve as previously reported [16].
Application of LR diagnostic models
Previously derived [5, 6] zone-specific LR models (as below)
were applied to calculate a predictive probability from the
quantitative mp-MRI metrics extracted at each ROI anatomi-
cal location (ADC, T2nSI, ME for the TZ and, ADC, T2nSI
and DCEnSI for the PZ).
TZ model : ln Oddsð Þ ¼ 5:347þ 0:332 ∙ ADC 0:974 ∙ T2nSI 1:730 ∙ ME
PZ model : ln Oddsð Þ ¼ 2:441  0:968 ∙ ADC  0:200 ∙ T2nSI
þ 2:546 ∙ DCEnSI
Two separate probability thresholds were then used to clas-
sify an ROI anatomical location as positive or negative by the
LR model.
The first threshold was based on the Youden index (J)
applied to the published model derivation 1.5 T mp-MRI
datasets [5, 6], where J is a function of sensitivity and speci-
ficity and is defined as the maximum vertical distance be-
tween the ROC curve and the diagonal line [17–20]. J occurs
at the threshold probability for optimal diagnostic models
classification ability. The maximum J within the PZ was J =
0.50, related to a probability threshold = 17%. For the TZ
maximum, J was 0.56, with probability threshold = 31%.
Table 1 Radiologists A and B
Likert scoring for the presence of
significant cancer within the PZ
and TZ in the cohort of patients
scanned at 3 T
Distribution of PZ Likert scores
Radiologist B Likert score
1 2 3 4 5 Total
Radiologist A Likert score 1 0 1 0 0 1 2
2 0 31 9 0 5 45
3 0 6 37 4 4 51
4 0 3 3 31 12 49
5 0 1 2 6 47 56
Total 0 42 51 41 69 203
Distribution of TZ Likert Scores
Radiologist B Likert score
1 2 3 4 5 Total
Radiologist A Likert score 1 0 0 0 2 0 2
2 0 97 18 4 2 121
3 0 11 26 3 1 41
4 0 0 0 6 3 9
5 0 2 1 1 26 30
Total 0 110 45 16 32 203
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The second threshold was set at a specificity of 50% from
the ROC analysis performed previously on at the time ofmodel
derivation using the original 1.5 T mp-MRI dataset [5, 6]. At
this specificity, the estimated probability threshold for the sig-
nificant disease was 14% for the PZ and 23% for the TZ.
Results
The ROC-AUC of the PZ and TZ LRmodels when applied to
the test dataset mp-MRI ROI anatomical location quantitative
metrics was 0.74 ± 0.04 (SD) and 0.68 + 0.04 (SD)
Fig. 3 Axial multi-parametric
MR images (a T2-weighted, b
apparent diffusion coefficient
map, c pre-contrast T1 and d early
post-contrast T1) of a region
(yellow arrows) in the transition
zone scored as equivocal (positive
tumour TPM biopsy) by the
radiologists
Fig. 2 Axial multi-parametric
MR images (a T2-weighted, b
apparent diffusion coefficient
map, c pre-contrast T1 and d early
post-contrast T1) of a region in
the peripheral zone scored as
equivocal (diffused lesion; posi-
tive tumour TPM biopsy) by the
radiologists
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respectively. The ROC-AUC for the zone-specific LR models
was similar to that for the experienced radiologist’s Likert
scores (Table 2). The agreement between radiologists A and
B Likert scores, calculated using Cohen’s kappa, was good
both in the PZ (κ = 0.625) and the TZ (κ = 0.609).
The sensitivities/specificities of the PZ model using the
Youden index and 50% specificity probability thresholds were
0.84/0.57 and 0.90/0.51 respectively, and for the TZ model
were 0.84/0.32 and 0.90/0.23 respectively (Table 3).
Radiologists A and B had sensitivities/specificities of 0.91/
0.40 and 0.90/0.33 in the PZ respectively and 0.58/0.75 and
0.60/0.65 in the TZ respectively (Likert ≥ 3 scored as
positive).
The PZ LR model with Youden index threshold classified
9% of patients as false positive and 20% as false negative; and
with 50% specificity probability threshold, 5% as false posi-
tive and 23% as false negative. In comparison, using a Likert
score threshold of ≥ 3 within the PZ as positive, radiologist A
classified 5% of patients as false positive and 28% as false
negative, whilst radiologist B classified 5% as false positive
and 31% as false negative.
The TZ LR model with Youden index threshold classified
7% of patients as false positive and 38% as false negative and
with 50% specificity probability threshold, 4% as false posi-
tive and 43% as false negative. In comparison, using a Likert
score threshold of ≥ 3 within the TZ as positive, radiologist A
classified 18% of patients as false positive and 14% as false
negative, whilst radiologist B classified 18% as false positive
and 20% as false negative.
Radiologist A scored 51 PZ cases and 41 TZ cases as
indeterminate (Likert 3/5). Application of LR models to the
Likert 3/5 group yielded a ROC-AUC 0.65 (95% CI 0.50–
0.80) for the PZ and ROC-AUC 0.74 (95% CI 0.58–0.90) for
the TZ (Figs. 4 and 5). The model correctly classified 86% of
PZ cases and 64% of TZ cases.
Radiologist B scored 51 PZ cases and 45 TZ cases as in-
determinate (Likert 3/5). Application of LR models to the
Likert 3/5 group yielded a ROC-AUC 0.67 (95% CI 0.51–
0.82) for the PZ and a ROC-AUC 0.69 (95% CI 0.62–0.77)
for the TZ (Figs. 4 and 5). The model correctly classified 92%
of PZ cases and 62% of TZ cases.
For areas that were scored by the radiologists as (highly)
likely or unlikely (Likert 1/5, 2/5, 4/5 and 5/5) to contain
significant cancer, the zone-specific LR models had similar
performance with the radiologists (Table 4)
& Radiologist A (Likert 1/5, 2/5, 4/5 and 5/5): The diagnos-
tic model had an ROC-AUC= 0.77 (95%CI 0.68–0.85) in
the PZ and 0.66 (95% CI 0.58–0.75) in the TZ.
Radiologist A had an ROC-AUC = 0.80 (95% CI 0.72–
0.87) in the PZ and 0.69 (95% CI 0.60–0.78) in the TZ.
& Radiologist B (Likert 1/5, 2/5, 4/5 and 5/5): The diagnos-
tic model had an ROC-AUC= 0.73 (95%CI 0.65–0.82) in
the PZ and 0.65 (95% CI 0.57–0.74) in the TZ.
Radiologist B had an ROC-AUC = 0.74 (95% CI 0.65–
0.83) in the PZ and 0.73 (95% CI 0.66–0.81) in the TZ.
Discussion
There were four principal observations. Firstly, we confirm
that the performance of both PZ and TZ LR models for clas-
sification of patients with significant tumour was comparable
to experienced radiologists.
Secondly, we highlight that zone-specific mp-MRI LR
models may help classify equivocal radiologist-scored areas
(Likert 3/5).
Thirdly, the examined zone-specific mp-MRI LR models
reliably classified significant cancers both in the PZ and the
TZ (the percentage of patients classified as false positives
ranged from 2 to 10%). In agreement with the PI-RADS v2
guidelines [21], the contribution of ADC is higher than the
contribution of T2 in the PZmodel, whereas for the TZmodel,
T2 has higher contribution than ADC.
Fourthly, by applying 1.5 Tmp-MRI-derived LRmodels to
an independent 3 T mp-MRI dataset, we have confirmed the
external validity and generalizability of the previously pub-
lished models [5, 6]. The generalizability can be attributed to
the selected quantitative MR parameters, which are calculated
as relative signal changes hence are less affected by the dif-
ferences during data acquisition between the training (1.5 T
magnet) and the independent (3 T magnet) cohort. This find-
ing is also supported by a previous study [6] where the exam-
ined TZ diagnostic model was applied on a temporal cohort of
TZ prostate cancer patients imaged at the same 1.5 T scanner.
This study showed similar results of the temporal validation
(ROC-AUC= 0.67) with the independent validation illustrat-
ed here (ROC-AUC = 0.68).
Our study evaluated previously reported 1.5 T mp-MRI
zone-specific diagnostic model performance on an
Table 2 ROC AUC of PZ and TZ LR models and comparative
experienced radiologist performance for classification of significant
cancer
Lower bound Upper bound
Peripheral zone
PZ model 0.74 0.04 0.67 0.81
Radiologist A 0.78 0.03 0.72 0.84
Radiologist B 0.74 0.04 0.67 0.81
Transition zone
TZ model 0.68 0.04 0.61 0.75
Radiologist A 0.69 0.04 0.61 0.77
Radiologist B 0.69 0.04 0.62 0.77
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independent cohort of patients scanned on a 3-TMR system to
evaluate their ability to aid radiologists. Separate validation of
the models was performed for areas identified as equivocal
that may practically aid experienced radiologists in predicting
tumour. Previous work from our group [22] also reported the
reverse scenario where zone-specific LR models were trained
in the 3 T mp-MRI dataset and applied on the 1.5 T mp-MRI
dataset. The reported ROC-AUCs were 0.76 (%CI 0.68–0.97)
in the PZ and 0.77 (%CI 0.66–0.89) in the TZ. Following a
sub-analysis, for the cases that were scored as indeterminate,
the ROC-AUCs were 0.72 (%CI 0.50–0.94) in the PZ and
0.77 (%CI 0.55–0.96) in the TZ. The reported ROC-AUCs
are similar to the ones reported in this work especially in the
PZ, but even in the TZ, the ROC-AUC differences are not
significantly different (p > 0.05).
In the current study, even though expert radiologists report-
ed the mp-MRI, diagnostic accuracy remainedmodest overall,
and almost a quarter of regions evaluated were classified as
equivocal for clinically significant cancer. This is in accor-
dance with other studies where up to 40% of the cases were
reported as indeterminate (using either the PI-RADS or the
Likert scoring) for the presence of cancer by the radiologist
after reviewing mp-MRI dataset [23]. Approximately 40% of
the cases classified as equivocal, contained significant cancer
on TPM histology in the PZ, and 46% of these contained
significant cancer on TPM histology in the TZ.
We found similar ROC-AUCs for the radiologist consensus
score and the derived mp-MRI diagnostic models. At first
glance, this suggests that the models would not benefit expe-
rienced radiologists working in consensus. However, the
ROC-AUC for radiologists’ evaluation does not reflect the
uncertainty of equivocal scores. When the diagnostic models
were evaluated on the radiologist A equivocal ROIs (51 in the
PZ and 41 in the TZ), 86% of PZ model predicted cases and
64% of TZ model predicted cases were correctly identified.
Similarly, when the diagnostic models were evaluated on the
radiologist B equivocal ROIs, 92% of PZ model predicted
cases and 62% of TZ model predicted cases were correctly
identified. Following a sub-analysis on the cases scored as
indeterminate by the radiologists the percentages of false pos-
itives predicted by the diagnostic models ranged from 2 to
10%. These results indicate that the zone-specific diagnostic
Table 3 Performance of PZ and
TZ models applied to 3 T mp-
MRI PICTURE trial dataset at (i)
Youdens index derived probabili-
ty threshold and (ii) at set 50%
specificity derived probability
threshold
Youdens index threshold 50% specificity threshold
Specificity Sensitivity Specificity Sensitivity
PZ model 0.57 0.84 0.51 0.90
TZ model 0.32 0.84 0.23 0.90
Sub-analysis on equivocal group (Likert score 3)
Radiologist A Radiologist B Radiologist A Radiologist B
Specificity/sensitivity Specificity/sensitivity Specificity/sensitivity Specificity/sensitivity
PZ model 0.42/0.75 0.52/0.61 0.39/0.90 0.48/0.78
TZ model 0.36/0.89 0.50/0.73 0.14/0.95 0.26/0.91
Fig. 4 ROC curve for LR model
classification of significant cancer
for equivocal radiologist scored
(Likert 3/5) PZ lesions from
radiologist A, ROC-AUC = 0.65
(95% CI 0.50–0.80), and
radiologist B, ROC-AUC = 0.67
(95% CI 0.51–0.82)
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models are trustworthy when classifying an indeterminate
case as significant cancer and that the diagnostic model may
indeed have the potential to aid even experienced radiologists.
Evidence is mounting for the use of mp-MRI to triage
patients prior to performing a prostate biopsy. Negative mp-
MRI is associated with about 1–2 in 20 risks of clinically
significant disease [24], whereas positive mp-MRI is associ-
ated with about 3 in 10 risks of clinically insignificant disease
[25, 26]. Equivocal mp-MRI scores would tend to be biopsied.
A tool to assist radiologists to avoid an equivocal category and
correctly identify those patients with a low risk of clinically
significant tumour would be of considerable value. Using the
clinically relevant probability threshold on the indeterminate
cases, the examined zone-specific mp-MRI models had (i)
sensitivity 90% in the PZ and 95% in the TZ for radiologist
A and (ii) sensitivity 78% in the PZ and 91% in the TZ for
radiologist B.
Our study has several limitations. We were reliant upon
visual matching of the Barzell zone histology on TPM and
ROIs on mp-MRI. Therefore, the results may be influenced
by misregistration errors. Although no biopsy is free from
sampling error [27], we used TPM to address as much of the
systematic error inherent to TRUS biopsy as possible [13, 28].
TPM also enables sampling in the anterior gland. Radical
prostatectomy specimens could not act as an alternative for
this study, as they would suffer from a large amount of
Fig. 5 ROC curve for LR model
classification of significant cancer
for equivocal radiologist scored
(Likert 3/5) TZ lesions from
radiologist A, ROC-AUC = 0.74
(95% CI 0.58–0.90), and
radiologist B, ROC-AUC = 0.69
(95% CI 0.62–0.77)
Table 4 ROCAUC of PZ and TZ
LR models and comparative
experienced radiologist
performance for areas that were
scored by the radiologists as
(highly) likely or unlikely (Likert
1/5, 2/5, 4/5 and 5/5) to contain
significant cancer
Area Std. error Asymptotic 95% confidence interval
Lower bound Upper bound
PZ areas scored by radiologist A as Likert = 1/5, 2/5, 4/5 and 5/5
PZ model 0.77 0.04 0.68 0.85
Radiologist A 0.80 0.03 0.72 0.87
PZ areas scored by radiologist B as Likert = 1/5, 2/5, 4/5 and 5/5
PZ model 0.73 0.04 0.65 0.82
Radiologist B 0.74 0.04 0.65 0.83
TZ areas scored by Radiologist A as Likert = 1/5, 2/5, 4/5 and 5/5
TZ model 0.66 0.05 0.58 0.75
Radiologist A 0.69 0.04 0.60 0.78
TZ areas scored by Radiologist B as Likert = 1/5, 2/5, 4/5 and 5/5
TZ model 0.65 0.05 0.57 0.74
Radiologist B 0.73 0.04 0.66 0.81
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selection bias given that they exclude men with no cancer and
represent a minority of all men diagnosed [29]. Moreover,
they also present technical challenges of accounting for dis-
tortion and gland shrinkage during fixing and the tissue loss in
preparing the whole mount which is not trivial [30]. The rel-
ative merits of each reference standard have been considered
before, but we believe TPM to be preferable in this patient
cohort as it includes patients negative for cancer but present-
ing an elevated PSA.
Conclusions
In summary, we have assessed the performance of zone-
specific mp-MRI diagnostic models for classification of
peripheral and transition zone signal, demonstrated their
similar performance to an experienced radiologist con-
sensus and highlighted their ability to classify equivocal
areas.
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